"super FVa
An Engineered Prohemostatic Agent for Hemophilia and Other Severe Bleeding Situations"

The topic of this talk will be super FVa, a novel prohemostatic FVa variant with enhanced biological activity and APC resistance. super FV was engineered with mutations of 3 activated protein C (APC) cleavage sites and a disulfide bond between the A2 and A3 domains. Data demonstrating this molecule’s excellent prohemostatic properties in hemophilic bleeding and other bleeding severe bleeding situations will be presented.